Marijuana as a whole plant has never been approved by the FDA for any medical condition. The agency has not approved a single marketing application for cannabis in any patient population, adult or pediatric. That said, the FDA has approved a small number of individual drugs derived from or related to cannabis, and the federal legal landscape is actively shifting.
What the FDA Has Actually Approved
While the cannabis plant itself lacks approval, four specific prescription medications containing cannabis-related compounds have cleared the FDA’s review process. These are manufactured drugs with standardized doses, not dispensary products.
Epidiolex is the only FDA-approved drug derived directly from the cannabis plant. Its active ingredient is cannabidiol (CBD), and it was approved in June 2018 for treating seizures associated with two severe forms of childhood epilepsy: Lennox-Gastaut syndrome and Dravet syndrome. It’s prescribed for patients two years of age and older.
Marinol and Syndros both contain dronabinol, a synthetic version of THC (the compound in marijuana that produces a high). They’re approved for two uses: appetite loss and weight loss in people with AIDS, and nausea and vomiting from cancer chemotherapy when other anti-nausea treatments haven’t worked. Cesamet contains nabilone, a different synthetic cannabinoid, and is approved for similar chemotherapy-related nausea.
These four drugs went through the same rigorous clinical trial process as any other prescription medication. That process is exactly what the whole marijuana plant has never completed.
Why the Whole Plant Hasn’t Been Approved
FDA approval requires a drug to demonstrate safety and effectiveness through controlled clinical trials. The marijuana plant contains hundreds of chemical compounds in varying concentrations depending on the strain, growing conditions, and preparation method. That variability makes it fundamentally different from a single purified molecule like the CBD in Epidiolex or the synthetic THC in Marinol.
Marijuana has also been classified as a Schedule I controlled substance since 1970, a category defined by “high potential for abuse” and “no currently accepted medical use.” That classification has historically created significant barriers to conducting the large-scale clinical trials needed for FDA approval, since researchers face extra layers of federal licensing and oversight to work with Schedule I substances.
The Rescheduling Effort
The federal government is in the process of potentially moving marijuana from Schedule I to Schedule III, which would place it alongside drugs like testosterone and certain codeine formulations. This process has been slow and procedural. The DEA announced a hearing on the proposal in August 2024, but delays pushed it into 2025. A hearing scheduled for January 21, 2025 was postponed due to a legal appeal.
In December 2025, President Trump issued an executive order directing the Attorney General to complete the rescheduling process as quickly as possible. Then in April 2026, Acting Attorney General Todd Blanche issued an order that immediately placed FDA-approved products containing marijuana and state-regulated medical marijuana products into Schedule III. A broader hearing on rescheduling all marijuana to Schedule III is set to begin June 29, 2026.
Rescheduling to Schedule III would not equal FDA approval. It would reduce federal restrictions on research and change how marijuana is regulated, but products sold at dispensaries would still lack the FDA’s stamp of safety and effectiveness. The distinction matters: Schedule III status means the government recognizes some accepted medical use, but individual products would still need to go through the approval process to make specific health claims.
What About State Medical Marijuana Programs?
More than three dozen states have legalized marijuana for medical use, and many also allow recreational sales. None of those state programs involve FDA oversight. The products you buy at a dispensary, whether flower, edibles, tinctures, or vapes, have not been evaluated by the FDA for safety, effectiveness, dosing consistency, or purity.
State programs set their own rules for testing, labeling, and qualifying medical conditions. Those standards vary widely. A product sold in one state’s medical dispensary might not meet another state’s requirements. This is a completely separate regulatory track from the federal drug approval process.
CBD Products Are Not FDA Approved Either
The explosion of CBD oils, gummies, and supplements on store shelves can create the impression that CBD has some kind of regulatory blessing. It doesn’t. With the sole exception of prescription Epidiolex, no CBD product has been approved by the FDA as safe and effective for any use. The FDA has not approved CBD as a dietary supplement or food additive, and products making health claims without approval are technically being sold illegally under federal law.
Safety Concerns With Unregulated Products
The gap between what’s legally available and what’s FDA approved creates real risks. The FDA and FTC have targeted companies selling delta-8 THC edibles in packaging designed to look like popular children’s snacks, including imitations of Froot Loops and Chips Ahoy cookies. These products pose a particular danger to children, who can suffer serious health consequences from accidental ingestion and are unlikely to read or understand warning labels on packaging that looks like their favorite treats.
Without FDA approval, there’s no federal guarantee that any cannabis product on the market contains what its label claims, is free from contaminants, or delivers a consistent dose. That’s true for dispensary products, gas station CBD, and everything in between. If you’re using cannabis for a medical purpose, the only products that have been through the FDA’s full safety review are the four prescription drugs listed above, and all require a doctor’s prescription.